Anixa Biosciences

Compare

485 Followers

ANIX Stock Chart & Stats

$4.29

-$0.08(-3.60%)

At close: Jan 08 4:00 PM EST

$4.29

-$0.08(-3.60%)

Day’s Range― - ―

52-Week Range$2.07 - $4.98

Previous CloseN/A

Volume56.82K

Average Volume (3M)262.44K

Market Cap

$139.57M

Enterprise ValueN/A

Total Cash (Recent Filing)$16.03M

Total Debt (Recent Filing)$213.00K

Price to Earnings (P/E)―

Beta0.44

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding32,916,916

10 Day Avg. Volume201,766

30 Day Avg. Volume262,435

Financial Highlights & Ratios

PEG Ratio-0.41

Price to Book (P/B)5.58

Price to Sales (P/S)0.00

P/FCF Ratio-15.22

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.50

Price Target Upside98.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressNo dose limiting toxicities observed in the 4th cohort; 5th cohort expected to start soon.

Strategic PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.

Survival BenchmarksSeveral treated patients remain alive beyond disease-specific median survival benchmarks.

Bears Say

Anixa Biosciences News

Anixa awarded patent in China covering breast cancer vaccine technology

Anixa Biosciences (ANIX) announced that the Chinese National Intellectual Property Administration, or CNIPA, has issued Patent Number ZL2020800215666,...

10d ago

ANIX

Anixa Biosciences completes patient visit in breast cancer vaccine trial

Anixa Biosciences (ANIX) announced the completion of the final patient visit in its breast cancer vaccine clinical trial....

23d ago

ANIX

Anixa announces final results from Phase 1 trial of breast cancer vaccine

Anixa Biosciences (ANIX) announced that final results from the Phase 1 clinical trial of its breast cancer vaccine...

1M ago

ANIX

Anixa Biosciences: Promising Clinical Progress and Financial Stability Underpin Buy Rating

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, retaining the price target of...

2M ago

ANIX

Anixa Biosciences files $200M mixed securities shelf

17:26 EDT Anixa Biosciences (ANIX) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

ANIX

Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating

Anixa Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

2M ago

ANIX

Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy

Anixa Biosciences (ANIX) announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical...

2M ago

ANIX

Anixa receives notice of allowance in China for cancer vaccine technology patent

Anixa Biosciences (ANIX) announced that the Chinese National Intellectual Property Administration, or CNIPA, has issued a Notice of...

2M ago

ANIX

Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort

Anixa Biosciences (ANIX) announced that the second patient in the fourth dose cohort has been treated in the...

2M ago

ANIX

Anixa Biosciences issued additional U.S. patent for CAR-T technology

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office has issued U.S. Patent Number 12,384,826...

3M ago

ANIX

Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences today and set a price target...

3M ago

ANIX

Anixa plans to begin Phase 2 of breast cancer vaccine trial

Anixa Biosciences (ANIX) announced that, in collaboration with Cleveland Clinic, it has initiated the transfer of the Investigational...

3M ago

ANIX

Anixa receives Notice of Allowance for breast cancer technology patent in Canada

Anixa Biosciences (ANIX) announced that the Canadian Intellectual Property Office, or CIPO, has issued a Notice of Allowance...

3M ago

ANIX

Anixa Biosciences Receives Buy Rating Amidst Strong Patent Portfolio and Promising Vaccine Trials

Anixa Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

3M ago

ANIX

ANIX FAQ

What was Anixa Biosciences’s price range in the past 12 months?

Anixa Biosciences lowest stock price was $2.07 and its highest was $4.98 in the past 12 months.

What is Anixa Biosciences’s market cap?

Anixa Biosciences’s market cap is $139.57M.

When is Anixa Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Anixa Biosciences’s earnings last quarter?

Anixa Biosciences released its earnings results on Mar 10, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.08.

Is Anixa Biosciences overvalued?

According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anixa Biosciences pay dividends?

Anixa Biosciences does not currently pay dividends.

What is Anixa Biosciences’s EPS estimate?

Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Anixa Biosciences have?

Anixa Biosciences has 32,916,916 shares outstanding.

What happened to Anixa Biosciences’s price movement after its last earnings report?

Anixa Biosciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -5.797%.

Which hedge fund is a major shareholder of Anixa Biosciences?

Currently, no hedge funds are holding shares in ANIX

Anixa Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-57.94%

Trailing 12-Months

Asset Growth

-22.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anixa Biosciences

Anixa Biosciences, Inc. is a biotechnology company focused on leveraging the body's immune system to develop treatments for cancer and infectious diseases. The company operates in the healthcare sector, specifically within the fields of immuno-oncology and infectious diseases. Its core offerings include the development of cancer immunotherapies and vaccines, aiming to innovate in the areas of cancer diagnostics and therapeutics.

Anixa Biosciences (ANIX) Earnings & Revenues

Historic Earnings Reports

ANIX Stock 12 Month Forecast

Average Price Target

$8.50

▲(98.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.6215384615384614,4.153076923076923,4.684615384615384,5.216153846153846,5.747692307692308,6.279230769230769,6.81076923076923,7.342307692307692,7.873846153846154,8.405384615384616,8.936923076923076,9.468461538461538,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.506153846153846,3.922307692307692,4.338461538461538,4.754615384615384,5.170769230769231,5.586923076923076,6.003076923076923,6.419230769230769,6.835384615384616,7.251538461538462,7.667692307692308,8.083846153846153,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.3907692307692305,3.691538461538461,3.9923076923076923,4.293076923076923,4.593846153846154,4.894615384615385,5.195384615384615,5.496153846153846,5.796923076923077,6.0976923076923075,6.398461538461539,6.69923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >